Together, these observations suggest that aberrant EGFR and TGF-β-dependent signaling pathways are pivotal in promoting pancreatic cancer progression and may represent crucial therapeutic targets in PDAC. The gene discussed is TGFB1; the disease is pancreatic neoplasm.